Acrizanib - 10mM in DMSO , CAS No.1229453-99-9

CAS: 1229453-99-9 Cat. No.: A656800 Fórmula: C20H18F3N7O2 Peso molecular: 445.40 PubChem CID: 59394698
Disponible para pedir
GRADE & PURITY 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Size
Alemania (EU)
USA*
Price
Qty
1ml
A656800-1ml
Fabricado bajo pedido · 8–12 semanas
764,39€
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Descripción general

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC 50 of 17.4 nM for BaF3-VEGFR-2

In Vitro

Acrizanib is a VEGFR-2 inhibitor, with an IC 50 of 17.4 nM for BaF3-KDR. Acrizanib (compound 35) exhibits ≤10% remaining kinase activity against only 13 wild type kinases: CSF1R, Kit, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, Fms (soluble VEGFR1), DDR1, DDR2, TIE1, and ABL1 (nonphosphorylated). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rat ocular PK studies with Acrizanib shows a distinctly different profile from that observed with compound 25. While prolonged exposure is once again evident in the PEC, the AUC ratio to the level of Acrizanib in plasma is markedly increased (>21000-fold higher exposure in the PEC than plasma on day 11). Furthermore, unlike 25, Acrizanib also afford much improved retina to plasma AUC exposure ratio after 10 days of dosing (598× for Acrizanib vs 0.8× for 25) . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:VEGFR-2 17.4 nM (IC 50 )

Specifications

Especificaciones y pureza
10mM in DMSO
Mecanismos bioquímicos y fisiológicos
Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC 50 of 17.4 nM for BaF3-VEGFR-2.
Condiciones de almacenamiento de almacenamiento
Store at -80°C
Enviado en
Dry ice packs + Cold packs
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Tipo de acción
INHIBITOR
Nombres e identificadores
Isómeros SMILES CNCC1=CC(=NC=N1)OC2=CC3=C(C=C2)N(C=C3)C(=O)NC4=NN(C(=C4)C(F)(F)F)C
CAS alternativo 1229453-99-9
PubChem CID 59394698
Términos de entrada MeSH acrizanib;LHA510;N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide
Peso molecular 445.40

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Objetivos asociados (humanos)
KDR Tclin Vascular endothelial growth factor receptor 2 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.